Gilead Sovaldi Sales
Analysts' estimate for Sovaldi sales is very conservative. Sovaldi TRx for the 6th week is about 2500. So if I usethis figure I get 2500x50(wks)x$60,000( discounted price/patient)=$7.5B for this year. But this does not includeany sales for Europe etc. which is even a bigger market than U.S. Also, this is only 6th week after its launch andthe TRx could get to 4000-5000 per week. Thus I would say Sovaldi sales could exceed $15B easily. Am I missingsomething or the Wall Street is totally wrong?